AR and prostate carcinoma: Studies of cultured prostate cancer cells and sequencing of prostate cancers have revealed multiple distinct subgroups of prostate cancer [17], including prostate cancer cells that are refractory to androgen treatment, that contain the androgen receptor splice variant AR-V7, or that express fusion proteins such as TMPRSS2-ERG.